H Lundbeck A/S v Sandoz Pty Ltd

Link copied
Case Copied 86 min read

FEDERAL COURT OF AUSTRALIA

H. Lundbeck A/S v Sandoz Pty Ltd [2018] FCA 1797

File numbers:

NSD 647 of 2014

NSD 824 of 2016

Judge:

JAGOT J

Date of judgment:

21 November 2018

Catchwords:

PATENTS – construction of claims – (+) and (−)-enantiomers – where patent claims separated (+)-enantiomer – no defence to infringement where only trace, trivial or insignificant amounts of (−)-enantiomer present in infringing products – claims of patent infringed

PATENTS – whether patentee/exclusive licensee prevented from brining infringement proceedings under provisions of the Patents Act 1990 (Cth)

CONTRACTS – construction of settlement agreement – licence to exploit the invention the subject of the patent in suit – licence no defence to infringement

DAMAGES – innocent infringement – discretionary defences – whether award of additional damages appropriate – assessment of damages for patent infringement – object of award of damages to restore patentee and/or exclusive licensee to the position each would have been in but for infringement

Legislation:

Acts Interpretation Act 1901 (Cth), s 12

Australian Consumer Law, s 18

Competition and Consumer Act 2010 (Cth)

Copyright Act 1968 (Cth), s115(4)

Designs Act 2003 (Cth), s 75(3)

Federal Court of Australia Act 1976 (Cth), s 51A

Patents Act 1952 (Cth)

Patents Act1990 (Cth), ss 3, 13, 15AB, 18, 32, 36, 40, 41, 42, 54, 55, 65, 67, 70, 71, 72, 75, 76, 77, 78, 79, 79C, 83, 85, 101E, 101F, 120, 122, 123, 133, 136H, 136J, 142, 143, 143A, 145, 147, 148, 149, 150, 151, 165A, 215, 223, 227 and 228

Trade Marks Act 1995 (Cth), s 126

Trade Practices Act 1974 (Cth)

Federal Court Rules 2011 (Cth), r 39.06

Patents Regulations 1991 (Cth), reg 22.21

Explanatory Memorandum, Patents Bill 1990 (Cth), cl 77  

Cases cited:

Actavis Pty Ltd v Orion Corporation [2016] FCAFC 121

Advanced Building Systems Pty Ltd v Ramset Fasteners (Aust) Pty Ltd [1995] FCA 236; (1995) AIPC 91-129

Advanced Building Systems Pty Ltd v Ramset Fasteners (Aust) Pty Ltd [2001] FCA 1098; (2001) 52 IPR 305

Alphapharm Pty Ltd vH Lundbeck A/S [2006] APO 18; (2006) 69 IPR 629

Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559; (2008) 76 IPR 618

Alphapharm Pty Ltd v H Lundbeck A/S [2011] APO 36; (2011) 92 IPR 628

Alphapharm Pty Ltd v H Lundbeck A/S [2014] APO 41; (2014) 109 IPR 323

Alphapharm Pty Ltd v H Lundbeck A/S [2014] HCA 42; (2014) 254 CLR 247

Alphapharm Pty Ltd v H Lundbeck A/S [2015] FCAFC 138; (2015) 234 FCR 306

Alphapharm Pty Ltd v H Lundbeck A/S [2014] FCA 1185; (2014) 110 IPR 59

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd(No 2) [2012] FCAFC 102; (2012) 204 FCR 494

Aristocrat Technologies Australia Pty Limited v DAP Services (Kempsey) Pty Limited (in liquidation) [2007] FCAFC 40; (2007) 157 FCR 564

Aspen Pharma Pty Ltd v Commissioner of Patents [2012] AATA 851; (2012) 132 ALD 648

Aspen Pharma Pty Ltd v…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read H Lundbeck A/S v Sandoz Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2018] FCA 1797
Decision Date

CaseChat Overview and Summary

The case of H Lundbeck A/S v Sandoz Pty Ltd involved a dispute over the infringement of Australian patent 623144, known as the Lexapro patent, which was owned by H Lundbeck A/S and licensed to Lundbeck Australia Pty Ltd. Sandoz Pty Ltd, a pharmaceutical company, was accused of manufacturing and selling a generic version of the patented drug escitalopram, which infringed the claims of the patent. The court was tasked with deciding whether Sandoz had infringed the patent, whether the patentee was prevented from bringing infringement proceedings, and if so, what damages should be awarded for the infringement.

The primary legal issues in the case were the construction of the patent claims and whether Sandoz's products infringed those claims. The court had to determine if the presence of trace, trivial, or insignificant amounts of a different enantiomer in Sandoz's products constituted an infringement. Another issue was whether the settlement agreement between Lundbeck and Sandoz provided a defense to the infringement claims. The court also considered whether additional damages were appropriate for innocent infringement and how to assess the damages for the patent infringement.

The court found that Sandoz's products did indeed infringe the claims of the 144 patent as the presence of trace amounts of a different enantiomer did not negate the infringement. The settlement agreement did not provide a defense to the infringement claims as it was a license to exploit the invention, not a defense to infringement. The court also determined that the award of additional damages for innocent infringement was not appropriate as the object of the award was to restore the patentee to the position they would have been in but for the infringement. The damages were to be calculated in a manner generally consistent with the approach of the accountant called by the applicants, subject to a discount of 30% to account for the risks associated with the past hypothetical cash-flows.

The final orders of the court included provisions for the confidentiality of the reasons for judgment, the provision of the reasons to the Patent Office, and the extension of time for filing a notice of appeal. The parties were also directed to propose further directions to finalize the litigation, including orders to enable the expert accounting witnesses to confer and provide a further joint report if necessary.

Orders

Orders of the court

1. Subject to order 2, until 5.00pm on 28 November 2018, pursuant to s 37AF of the Federal Court of Australia Act 1976 (Cth) and on the ground that it is necessary to prevent prejudice to the proper administration of justice under s 37AG(1)(a), there be no disclosure (by publication or otherwise) of the reasons for judgment delivered on the date of this order in proceedings NSD 647 of 2014 and NSD 826 of 2016 (Proceedings) to any person other than to the external solicitors, expert accounting witnesses, and counsel for the parties in the Proceedings and Lundbeck In-house Counsel and Sandoz In-house Counsel (as defined in the Confidentiality Agreement dated 30 May 2017).

2. The reasons for judgment may be provided to the Patent Office in relation to the Application for Licence to Exploit an Invention made by the Respondent to the Patent Office on 18 December 2013, provided that the Commissioner of Patents makes a direction under regulation 4.3(2)(a) and / or 4.3(2)(b) that the reasons for judgment will not be open to public inspection pending the making of any confidentiality orders referred to in order 6.

3. By 4.00pm on 28 November 2018 any party wishing to claim that any part of the reasons for the judgment should be subject to a further confidentiality order is to notify the Associate to Jagot J and the other parties, by email of the claim including:

(a) details of the matter claimed to be confidential;

(b) a short statement of the reasons the matter is said to be confidential; and

(c) a statement identifying whether the claimant consents to the confidentiality claim being determined by Jagot J on the basis of the email or seeks an oral hearing.

4. If no notice by email is received in accordance with order 3, the reasons for judgment will be published forthwith.

5. If notice is received in accordance with order 3, the reasons for judgment will be published forthwith with the claimed confidential matter redacted pending determination of the confidentiality claim.

6. The parties are to confer and, by 4.00pm on 5 December 2018, are to propose in a joint email (including agreed and disagreed matters) to the Associate to Jagot J further directions to enable the matter to be finalised, including orders to enable the expert accounting witnesses to confer and provide a further joint report, if necessary, in respect of any outstanding issues having regard to the reasons for judgment.

7. Pursuant to rule 36.03(b) of the Federal Court Rules 2011 (Cth), the time within which a party may file and serve any notice of appeal from judgment in these proceedings be extended to and for a period of 21 days after the publication of the reasons for judgment pursuant to orders 4 or 5, or the date of the determination of any outstanding issues raised by the expert accounting witnesses in any further joint report pursuant to order 6, whichever is later.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

These reasons for judgment explain why I have decided that the applicants’ claims for patent infringement and misleading and deceptive conduct against the only remaining respondent should succeed and be subject to an award of damages calculated in a manner generally consistent with the approach of the accountant called by the applicants, but subject to a discount of 30% to take account of all relevant risks associated with the past hypothetical cash-flows which underlie the assessment of damages.2. The essential facts H Lundbeck A/S (referred to as Lundbeck A/S or Lundbeck DN) is the patentee of Australian patent 623144 (the 144 patent or the Lexapro patent). Lundbeck Australia Pty Ltd (referred to as Lundbeck AU), a subsidiary of Lundbeck A/S, claims to be the exclusive licensee of the 144 patent. Lundbeck AU sells Lexapro and Cipramil in Australia which are manufactured by and purchased from Lundbeck A/S. CNS Pharma Pty Ltd is a subsidiary of Lundbeck AU which sells a generic version of Lexapro in Australia known as Esipram which is also manufactured by and purchased from Lundbeck A/S. Lundbeck A/S and Lundbeck AU, when there is no need to distinguish between them, are referred to in these reasons as Lundbeck. The 144 patent is dated 13 June 1989 and thus its term of 20 years under s 67 of the Patents Act1990 (Cth) meant that, if the term was not extended, the patent would expire on 13 June 2009. Lundbeck A/S applied to extend the term of the 144 patent on 22 December 2003. The Commissioner of Patents granted the extension so that the 144 patent would not expire until 13 June 2014. Alphapharm Pty Ltd contended to the Commissioner that the extension was invalid and that the only extension which could have been granted was until 9 December 2012. The Commissioner agreed with Alphapharm’s contention and scheduled a hearing to decide if the Commissioner should amend the extended term to 9 December 2012. Alphapharm commenced a proceeding to revoke claims 1 to 6 of the 144 patent and to remove the extension of term until 13 June 2014 from the Register of Patents. Lundbeck commenced a proceeding to prevent the Commissioner from amending the Register by contending that a relevant regulation was invalid. Lundbeck also cross-claimed against Alphapharm for infringement of the 144 patent. On 1 March 2006 Lindgren J dismissed Lundbeck’s application contending invalidity of the regulation: H Lundbeck A/S v Commissioner of Patents [2006] FCA 163; (2006) 150 FCR 269. In so doing Lindgren J exposed the competing positions of the parties. Lundbeck relied on the registration of escitalopram oxalate on the Australian Register of Therapeutic Goods (ARTG) on 16 September 2003 as the relevant date for the extension. This is known as the Lexapro registration (Lexapro being the brand name of Lundbeck’s escitalopram oxalate product). Alphapharm contended that the relevant date was that on which citalopram hydrobromide was registered on the ARTG, being 9 December 1997. This is known as the Cipramil registration (Cipramil being the brand name of Lundbeck’s citalopram hydrobromide product). As Lindgren J explained at [13]:Subsection 71(2) of the Act provides that an application for an extension of term must be made during the term of the patent and within six months of the latest of the following dates:‘(a) the date the patent was granted;(b) the date of commencement of the first inclusion in the [ARTG] of goods that contain, or consist of, any of the pharmaceutical substances referred to in subs 70(3);(c) the date of commencement of [s 71].’In this case, on either of the competing views the latest of those three dates is that referred to in para (b). If the date referred to in para (b) was, as Lundbeck contends, 16 September 2003, Lundbeck had until 16 March 2004 in which to apply for the extension, and therefore its application made on 22 December 2003 was within time. If, on the other hand, the date referred to in para (b) was, as Alphapharm contends, 9 December 1997, Lundbeck had only until 9 June 1998 in which to apply for an extension, and, therefore, its application on 22 December 2003 was made out of time.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

However, as Lundbeck submitted, and consistent with my conclusions above about Lundbeck’s conduct being reasonable and Sandoz having supplied its products at risk based on its own commercial calculations, Sandoz’s contentions in this regard are without merit as:Lundbeck did not encourage or countenance the impugned conduct of Sandoz. To the contrary, Sandoz knowingly launched at risk of infringement allegations being made by Lundbeck. In due course, Lundbeck pursued its infringement case at the earliest opportunity. 24. Conclusions Lundbeck should succeed in its claims for damages for patent infringement generally in accordance with the approach taken by Mr Stone, subject to an overall discount of 30% to take account of the risks which I have identified in these reasons for judgment. I am aware that Mr Stone’s further calculations provided to the Court by email on 13 November 2018 have not yet been reviewed by Mr Samuel. Further orders will provide this opportunity for review to Mr Samuel and for both Mr Stone and Mr Samuel to inform me of any outstanding issues about the calculations provided that these reasons for judgment are used as the basis for them. I am also aware that Sandoz has pleaded that if it required a licence from Lundbeck to supply its escitalopram products (which, on my conclusions, it did from 15 June 2009 until 9 December 2012 and did not have a licence (which I have concluded it did not), then it has applied for such a licence under s 223(9) of the Patents Act. I have been informed that the application for a licence will be heard on 19 and 20 November 2018. My preliminary view is that the appropriate way to deal with this is for me to make final orders as appropriate once all required calculations are complete and for me to hear and determine any application for a stay of those orders as appropriate. Before general publication of these reasons for judgment, the parties should also be given an opportunity to consider these reasons for the purpose of deciding if any claim for confidentiality should be made and proposing further directions to bring this long-running litigation to an end as soon as possible.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.